Pfizer, Mylan Can't Quickly Appeal EpiPen RICO Class Cert.

By Hannah Albarazi · May 26, 2020, 11:10 PM EDT

EpiPen manufacturer Pfizer and distributor Mylan cannot immediately appeal a Kansas federal judge's certification of a nationwide class under the Racketeer Influenced and Corrupt Organizations Act in multidistrict litigation over the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Hannah

November 20, 2024
Hospital's Med Mal Win Axed By Mich. Appeals Panel
November 15, 2024
Abbott Inks $8M Deal With Healthcare Fraudster In TM Suit
November 04, 2024
DOD Trans Healthcare Denial Discriminates, Judge Rules
October 29, 2024
Retired Fed. Circ. Judge Backs Invisalign In Monopoly Cases
October 11, 2024
Apple Watch Patents Dodge Ax As Masimo Jury Trial Nears
October 01, 2024
From AI To Enviro: The Top Biz Bills Calif. Gov. Inked Into Law
September 27, 2024
Why Many Drugs Remain Pricey 40 Years After Hatch-Waxman
September 11, 2024
Top Calif. Biz Bills Sitting On Gov. Newsom's Desk
September 03, 2024
3rd Circ.: Biotech Must Pay Royalties Despite Expired Patents
August 20, 2024
Ala. AG Can't Prosecute Aiding Abortion Travel, DOJ Says